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enact more stringent price controls. The purpose of this study is to provide empir-
ical evidence on how price regulations in the OECD affected the adoption speed of
new patent-protected pharmaceutical technologies during 1999-2008. METHODS:
We use discrete time duration modelling with parametric and semi-parametric
duration dependence to examine how price expectations shape the probability of
launch, controlling for competition, market size expectations, firm and molecule
heterogeneity across the major OECD markets during 1999-2008. A sub-sample
analysis including only EU countries also investigates the impact of price interde-
pendencies and potential firm strategies in launch and pricing decisions. RESULTS:
The empirical analysis suggests there is a statistically significant and robust price
and market size effect in the adoption of new pharmaceutical technologies. A unit
increase in the log expected launch price and the log of expected market size
increases the probability of launch by 0.003 and 0.002 respectively. Concentrated
therapeutic subgroups, reflecting market crowding constitutes a significant barrier
to entry. Sub-sample findings from the EU market suggest strategic firm behaviour
with firms delaying launch in low-priced markets and attempts to maintain price
differentials across interdependent markets to a minimum due to price comple-
mentarities. Firm economies of scale and the therapeutic importance of innova-
tions are other important drivers of early adoption. CONCLUSIONS: A significant
and robust price and market size effect is observed in the likelihood of new phar-
maceutical adoption. Price regulations slow down pharmaceutical adoption on a
global scale and may impose welfare losses, particularly when the innovations that
are delayed are cost-effective from a societal perspective. Due to scale advantages
observed in international roll-out strategies, price controls may increase incentives
for mergers and acquisitions, further increasing concentration levels and barriers
to entry.
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OBJECTIVES: To understand the role of discounts/rebates impacting medicines
prices in hospitals. METHODS: Qualitative survey with competent authorities and
hospital pharmacists about purchasing strategies for hospital medicines with all
EU Member States and two further European countries (Norway, Turkey) Price
survey (study visits) of 12 active ingredients in 25 hospitals in Austria, the The
Netherlands, Norway, Portugal, Slovakia. RESULTS:Of a total of 27 European coun-
tries, 25 countries reported about the practice of discounts and/or rebates (ex-post
price reductions). The range of the discounts varied among the countries and with
regard to the products. Apart from Italy with mandatory discounts to the NHS,
discounts were always commercial and as such usually kept confidential. Free-cost
medicines (i.e. medicines provided without payment) were reported to be a prac-
tice in six countries, whereas it is legally forbidden in another six countries. In
Austria, the The Netherlands, Portugal, and Slovakia discounts were granted in
individual negotiations between suppliers and hospitals for some of the surveyed
products (e.g., for cardiovascular medicines where generics were available; how-
ever no discounts for all oncology medicines of the sample). In Norway, discounts
played no role since medicines were tendered centrally. In Austria and Slovakia
medicines were provided cost-free to some/all hospitals (only in the indication of
cardiovascular treatment). In Portugal, unit prices of nearly € 0.00 were surveyed
for a few cardiovascular medicines attributable to rebates. CONCLUSIONS: In the
in-patient sector, confidential discounts, and, to a lesser extent, rebates and cost-
free medicines are common in some countries. Discounts are more likely to be
provided where there are (off-patent) therapeutic alternatives available. Large dis-
counts and cost-free provision appear to be a practice for “strategic products”
which account for high volume and expenditure in the out-patient sector.
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OBJECTIVES: The increase in premium-priced orphan drugs coupled with health
care budget constraints will pressure managed care plans to consider restricting
market access. Coverage and reimbursement of ten FDA-designated orphan drugs
(ceramide, alglucerase, modafinil, lamotrigine, laronidase, nitisinone, alpha-gluco-
sidase, galsulfase, idursulfase, bosentan) were analyzed for ten popular Medicare
PDP (AARP, Cigna, CVS Caremark, Humana, Medco, RxAmerica, EmblemHealth,
UniCare, WellCare, FirstHealth.METHODS: Formulary tier structure, out-of-pocket
costs (OPC), monthly retail costs and utilization restrictions (UR)—pre-authoriza-
tion (PA), quantity limits (QL) and step therapy (ST)—were obtained from CMS
(www.medicare.gov). UR were assigned point values reflecting most to least re-
strictive—PA, 3; ST, 2; QL, 1; 6 possible points per drug per plan unless excluded
from formulary. OPC is the percentage of the drugs’ costs paid by patients—an
average of deductible, initial, gap, and catastrophic OPC. Disease incidences were
obtained from a variety of sources. RESULTS: Monthly retail prices ranged from
$19.56 (lamotrigine; generic) to $5,946.37 (bosentan). The drugs excluded from the
most formularies were alglucerase and myozyme (3 each). Lamotrigine, the least
expensive drug, had the highest OPC as a percentage of its retail price (57.58%) on
average among the plans; however, this may be because of its low retail price.
Bosentan had the lowest OPC (36.48%). There was no correlation between drug
price and UR points (r20.030). There were a slight positive correlation between
disease incidence and drug price (r20.219) and between disease incidence and
OPC (r20.380). There were slight negative correlations between a drug’s UR points
and its OPC percentage (r20.163) and between its retail price and OPC (r20.423).
CONCLUSIONS: URs on orphan drugs were prevalent in Medicare plans, with pa-
tients bearing 40-60% of the OPC. The extent of restrictions was not proportional to
the drugs’ price, suggesting that more research is warranted to investigate the
factors related to orphan drug access.
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OBJECTIVES: Pharmaceutical drug costs represent a large portion of government
health care spending. A national standard to regulate the process of public finan-
cial reimbursement for drugs does not exist in Canada and variations in practices
are evident across the country. The purpose of this study was to provide a compre-
hensive overview of how drug-funding decisions are made in Ontario. METHODS:
Access to Ontario’s Committee to Evaluate Drugs (CED) meeting minutes (July 2009-
July 2010) was granted. A data abstraction form was created based on the frame-
work established by Johnson et al. (2009). For each criterion, importance to the final
decision, strength of evidence and quality of evidence were recorded. Two review-
ers independently extracted the information and consensus was achieved.
RESULTS: Forty-four submissions were included. Five main observations: 1) the
CED considered certain criteria more frequently than others (e.g., clinical benefit
was considered for all decisions, while societal values were discussed less fre-
quently); 2) the relative impact of each criterion on the CED’s recommendation
varied (e.g., overall clinical benefit, efficacy, value for money, and need had the
largest influence); 3) the CED was more likely to discuss the strength of evidence
when its recommendation did not support public funding (e.g., the strength of cost
evidence was discussed 3 times more often for those drugs not recommended for
funding); 4) the frequency with which the CED considered criteria varied according
to whether or not the CED believed there was an established need; and 5) the
majority of the comments made by the CED about the strength of evidence indi-
cated that the quality of the data was low. CONCLUSIONS: This review identified
trends in the influence of different criteria involved in the CED’s drug assessment
process. These results may promote the development and application of a com-
prehensive, consistent, and transparent framework for reimbursement decision-
making.
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BACKGROUND: Pharmaceutical consultation (PC) aims to maximize the successful
outcome of a drug treatment. Although its benefits are well documented, several
different PC models are implemented in various healthcare settings (HCS) and no
optimal model has been identified. OBJECTIVES: To analyze the characteristics of
PC models most relevant to key clinical, monetary, and social objectives, and to
design PC models that optimize them and could be implemented in various HCS
and in primary care in Israel. METHODS:We systematically reviewed studies of PC
programs published from 2000–2010. We analyzed the programs by their organi-
zational characteristics and defined a scale for measuring their success that incor-
porated the clinical, monetary and social objectives. Their results were then scored
accordingly. We calculated the association between each of the key organizational
characteristics and the success score to identify the characteristics that maximize
the program’s success. RESULTS: The analysis revealed three core patterns: con-
sultation to patient and physician, patient alone, and physician alone. For each
pattern, three feasible models for optimal PC were found. The organizational char-
acteristics of each model included the subject and location of the consultation,
target population, consultant’s profession, communication method, incentives,
duration, financing, and the PC process steps. CONCLUSIONS: This method for
optimizing a model for PC program could be implemented in a variety of HCS to
maximize successful drug treatment reflected in the prevention and control of
illnesses, improved clinical outcomes, enhanced well-being of the population and
maximum economic benefits. Interviews with a sample of key players in HCS could
reveal preferences and benefits, which then will be combined with the results of
the previous analysis to optimize a PC program for primary care in Israel and for
other HCS.
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OBJECTIVES: Regenerative medicines, which include cellular and gene therapies,
offer to shift the focus of healthcare from one of palliative care to curative treat-
ment. Because these technologies are novel, more complex than standard biophar-
maceuticals, and often costly, they are anticipated to face heavy scrutiny for mar-
ket access and adoption. The objective of this analysis was to evaluate published
HTAs and reimbursement policies on regenerative medicines for select global mar-
kets, compare them to existing biopharmaceuticals, and evaluate lessons for HEOR
and market access planning. METHODS: A search of HTAs and reimbursement
policies from Australia, Canada, France, Germany, Sweden, the UK (UK) and the
United States (US) was conducted to identify reimbursement recommendations
and key HEOR considerations for this new field. A review of the literature, including
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